Infectious Diseases

Top Medical News
Comorbidities affect immune response to severe COVID-19
Yesterday
Immune signatures developed in response to severe COVID-19 appear to vary not only according to the principal disease but also with underlying comorbidities, such as hypertension, diabetes, and heart diseases, a new study has found.
H. pylori eradication: Triple therapy with 1-week vonoprazan as good as with 2-week PPI
2 days ago
One-week vonoprazan-based triple therapy is well tolerated and has comparable efficacy as the 2-week proton pump inhibitor (PPI)-based triple therapy for first-line Helicobacter pylori eradication, according to a study.
Vitamin D COVID-19
Kanas Chan, 4 days ago

Vitamin D deficiency is common in modern society, particularly among older people who are homebound. Vitamin D supplements in older people may have a role in preventing serious complications of COVID-19, according to data presented at AIM 2022.

HBcrAg, HBsAb levels tied to persistent functional chronic hepatitis B cure
4 days ago
In chronic hepatitis B (CHB) patients treated with pegylated interferon alpha (peg-IFN-α)-based interventions, lower levels of the HB core-related antigen (HBcrAg) and higher levels of the HB surface antibody (HbsAb) are associated with durable functional cure, a recent study has found,
How effective were COVID-19 antivirals during HK’s Omicron BA.2 wave?
Christina Lau, 5 days ago

A real-world study during Hong Kong’s Omicron BA.2 wave showed that both molnupiravir and nirmatrelvir/ritonavir effectively lowered the risks of disease progression and all-cause mortality in hospitalized COVID-19 patients not requiring oxygen supplementation on admission. However, mortality risk reduction was larger with nirmatrelvir/ritonavir vs molnupiravir.

Intravenous push shortens time to initiation of antibiotics in ED
Stephen Padilla, 6 days ago
Administration of ampicillin/sulbactam, piperacillin/tazobactam, and ertapenem via intravenous push (IVP) results in better times to initiation of empiric, first-dose antibiotics in the emergency department, (ED) without increasing the incidence of adverse events (AEs), a study has shown.
Special Reports
Product Highlight - Canespro
15 Jun 2022
Bifonazole Anti-Fungal Cream 1% w/w
Kids hard-hit by Delta; which ART performs best?
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Rapid antigen test: Don’t let perfect be the enemy of good
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
ID NOW rapid molecular assay an effective COVID-19 test for kids
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Product Highlight - Cresemba
29 Sep 2021
Isavuconazole 100 mg hard cap and 200 mg infusion conc
Antigen rapid tests: The new COVID-19 strategy moving forward?
Roshini Claire Anthony, 31 Jul 2021

Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.

Conference Reports
Vitamin D COVID-19
Kanas Chan, 22 Jun 2022

Vitamin D deficiency is common in modern society, particularly among older people who are homebound. Vitamin D supplements in older people may have a role in preventing serious complications of COVID-19, according to data presented at AIM 2022.

How effective were COVID-19 antivirals during HK’s Omicron BA.2 wave?
Christina Lau, 21 Jun 2022

A real-world study during Hong Kong’s Omicron BA.2 wave showed that both molnupiravir and nirmatrelvir/ritonavir effectively lowered the risks of disease progression and all-cause mortality in hospitalized COVID-19 patients not requiring oxygen supplementation on admission. However, mortality risk reduction was larger with nirmatrelvir/ritonavir vs molnupiravir.

Imatinib may reduce mortality in hospitalized COVID-19 patients
Roshini Claire Anthony, 06 Jun 2022

The tyrosine kinase inhibitor imatinib may reduce mortality in patients hospitalized with severe COVID-19, according to follow-up results of the CounterCOVID study presented at ATS 2022.

BLU-5937 may SOOTHE refractory cough
Audrey Abella, 30 May 2022
Individuals with refractory chronic cough (RCC) may find relief in BLU-5937, a selective P2X3 antagonist under development which showed favourable efficacy in reducing cough frequency in the phase IIb SOOTHE trial.
Rapid MRSA and S aureus decolonization reduces prosthetic joint infections
Elvira Manzano, 26 May 2022
Screening for and decolonization of Staphylococcus aureus, as well as timely use of surgical antimicrobial prophylaxis, reduces prosthetic joint infections in elderly patients with methicillin-resistant S. aureus (MRSA) undergoing hip surgery, reports an expert at ECCMID 2022.
Long COVID: What factors contribute to the risk?
Roshini Claire Anthony, 25 May 2022

Only a minority of patients are considered fully recovered 1 year after being discharged from hospital due to COVID-19, with women and obese individuals at increased risk of long COVID, according to results of the prospective PHOSP-COVID* study presented at ECCMID 2022 and published in The Lancet.

Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant
Roshini Claire Anthony, 23 May 2022

Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.